Business
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial a
About this update from Boston Scientific Corporation
[{"type":"text","content":"Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation ","length":204,"tagName":"p","attribs":{}},{"type":"text","content":"Late-breaking findings presented at ACC.26 and simultaneously published in The New England Journal of Medicine","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in The New England Journal of Medicine.","length":715,"tagName":"p"},{"type":"image","alt":"Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation) (PRNewsfoto/Boston Scientific Corporation)","displaySize":"","headline":null,"caption":"Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation) (PRNewsfoto/Boston Scientific Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/02e6d5e710acee0e3d3509b5490e4888"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IvXqbUK0RYM7N8cKg1j92g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2OA--/https://media.zenfs.com/en/prnewswire.com/02e6d5e710acee0e3d3509b5490e4888","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/329537/Boston_Scientific_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Atrial fibrillation (AF) is an increasingly common heart rhythm disorder that affects approximately 59 million people worldwide1 and increases stroke risk by five times compared to people with a normal heart rhythm.2 In patients with NVAF, more t...